[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-364211-105":59,"doc-detail-364211-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","oncosexome-the-landscape-of-sex-based-differences-in-oncologic-diseases","OncoSexome - the landscape of sex-based differences in oncologic diseases","","NIH policy on sex as biological variable (SABV) highlights sex-based differences as a core element of precision oncology, supported by evidence that more than half of clinically actionable oncology genes are sex-biased and can influence drug efficacy. Prior studies report sex disparities in multiple non-reproductive cancers, yet comprehensive cancer datasets remain limited. OncoSexome is introduced as a multidimensional knowledge base that organizes sex-associated variation across antineoplastic drugs and responses, oncology biomarkers, risk factors, and the microbial landscape.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/oncosexome-the-landscape-of-sex-based-differences-in-oncologic-diseases/364211/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/oncosexome-the-landscape-of-sex-based-differences-in-oncologic-diseases/364211.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What does the NIH SABV policy imply for precision oncology?","Question",{"text":113,"@type":114},"It emphasizes that sex-based differences must be adequately considered in cancer research and trials to support precision oncology decisions.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What four topics does OncoSexome cover?",{"text":118,"@type":114},"OncoSexome organizes sex-based differences across antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF), and microbial landscape (SML).",{"name":120,"@type":111,"acceptedAnswer":121},"Why is OncoSexome expected to be important for future cancer research?",{"text":122,"@type":114},"Because it integrates multifaceted, sex-associated external and endogenous contributors to cancer development across broad oncologic classes, addressing growing global interest in sex-based differences.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},364211,1790270079,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","Nucleic Acids Research, 2025, 53, D1443–D1459  \n[https://doi.org/10.1093/nar/gkae1003](https://doi.org/10.1093/nar/gkae1003)  \nAdvance access publication date: 13 November 2024  \nDatabase issue  \nOncoSexome: the landscape of sex-based differences in oncologic diseases  \nXinyi Shen1 ,2 ,†, Yintao Zhang1 ,†, Jiamin Li3 , Ying Zhou1 , Samuel D. Butensky4 , Yechi Zhang2 ,5 , Zongwei Cai 3 , Andrew T. DeWan6 , Sajid A. Khan4 , 7 , Hong Yan3 , *, Caroline H. Johnson2 , * and Feng Zhu 1 ,8 , *  \n1 College of Pharmaceutical Sciences, The Second Affiliated Hospital, Zhejiang University School of Medicine, State Key Laboratory of Advanced Drug Delivery and Release Systems, Zhejiang University, Hangzhou 310058, China  \n2 Department of Environmental Health Sciences, Yale School of Public Health, Yale University, New Haven 06510, USA  \n3 State Key Laboratory of Environmental and Biological Analysis, Department of Chemistry, Hong Kong Baptist University, Hong Kong 999077, China  \n4Yale School of Medicine, Yale University, New Haven 06510, USA  \n5 School of Public Health, Zhejiang University, Hangzhou 310058, China  \n6 Department of Chronic Disease Epidemiology, Yale School of Public Health, Yale University, New Haven 06510, USA  \n7 Division of Surgical Oncology, Department of Surgery, Yale School of Medicine, New Haven 06510, USA  \n8 Innovation Institute for Artificial Intelligence in Medicine of Zhejiang University, Alibaba-Zhejiang University Joint Research Center of Future Digital Healthcare, Hangzhou 330110, China  \n* To whom correspondence should be addressed. Tel: +86 189 8946 6518; Email: [zhufeng@zju.edu.cn](zhufeng@zju.edu.cn)[ ](zhufeng@zju.edu.cn)Correspondence may also be addressed to Caroline H. Johnson. Email: [caroline.johnson@yale.edu](caroline.johnson@yale.edu)[ ](caroline.johnson@yale.edu)Correspondence may also be addressed to Hong Yan. Email: [hongyan@hkbu.edu.hk](hongyan@hkbu.edu.hk)  \n†These authors contributed equally to this work as co-first authors.  \nAbstract  \nThe NIH policy on sex as biological variable (SABV) emphasized the importance of sex-based differences in precision oncology. Over 50% of clinically actionable oncology genes are sex-biased, indicating differences in drug efficacy. Research has identified sex differences in non-reproductive cancers, highlighting the need for comprehensive sex-based cancer data. We therefore developed OncoSexome, a multidimensional knowledge base describing sex-based differences in cancer ([https://idrblab.org/OncoSexome/](https://idrblab.org/OncoSexome/)) across four key topics: antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF) and microbial landscape (SML) . SDR covers sex-based differences in 2051 anticancer drugs; SBM describes 12 551 sex-differential biomarkers; SRF illustrates 350 sex-dependent risk factors; SML demonstrates 1386 microbes with sex-differential abundances associated with cancer development. OncoSexome is unique in illuminating multifaceted influences of biological sex on cancer, providing both external and endogenous contributors to cancer development and describing sex-based differences for the broadest oncological classes. Given the increasing global research interest in sex-based differences, OncoSexome is expected to impact future precision oncology practices significantly.  \nGraphical abstract  \nReceived: August 6, 2024. Revised: September 28, 2024. Editorial Decision: October 12, 2024. Accepted: October 16, 2024  \n© The Author(s) 2024. Published by Oxford University Press on behalf of Nucleic Acids Research.  \nThis is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License  \n([https:](https://creativecommons.org/licenses/by-nc/4.0/)[//](https://creativecommons.org/licenses/by-nc/4.0/)[creativecommons.org](https://creativecommons.org/licenses/by-nc/4.0/)[/](https://creativecommons.org/licenses/by-nc/4.0/)[licenses](https://creativecommons.org/licenses/","cbCaikZxNO6UGA9v","https://ap.wps.com/l/cbCaikZxNO6UGA9v","pdf",2692077,17,"English","# Abstract\n## OncoSexome knowledge base (SDR, SBM, SRF, SML)\n## Introduction and sex differences in cancer","[{\"question\":\"What does the NIH SABV policy imply for precision oncology?\",\"answer\":\"It emphasizes that sex-based differences must be adequately considered in cancer research and trials to support precision oncology decisions.\"},{\"question\":\"What four topics does OncoSexome cover?\",\"answer\":\"OncoSexome organizes sex-based differences across antineoplastic drugs and responses (SDR), oncology-related biomarkers (SBM), risk factors (SRF), and microbial landscape (SML).\"},{\"question\":\"Why is OncoSexome expected to be important for future cancer research?\",\"answer\":\"Because it integrates multifaceted, sex-associated external and endogenous contributors to cancer development across broad oncologic classes, addressing growing global interest in sex-based differences.\"}]","OncoSexome - the landscape of sex-based differences in oncologic diseases | PDF",1790156463,43,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/49712df5ef4f144d9a6c404544996a4e.webp",983,1272,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dda538a4bb26773aae09e5a887435dda.webp",982,1270,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5cd0b5ad7bdee36dba6ba013be8201c4.webp",981,1269,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c23d951f3d3a73cb60bdbb7b734bdee3.webp",980,1268]